Panbela Therapeutics Inc

Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The firm’s product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in multiple tumor types. The company was founded by Michael T. Cullen, Jr. and Thomas X. Neenan on September 21, 2011 and is headquartered in Waconia, MN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Panbela Therapeutics reports Q1 progress in cancer trials amid financial challenges

Panbela Therapeutics showcased progress in clinical trials but faces financial challenges with a significant net loss and limited cash reserves.
The company's focus on innovative treatments for cancer presents growth opportunities, although delays in trial analysis and stock exchange shifts pose risks.
Overall, Panbela's strategic advancements in oncology treatments position it for potential growth pending financial stability and successful trial outcomes.

Panbela Therapeutics reports Q2 progress amidst financial challenges and opportunities

Panbela Therapeutics Inc's Q2 2024 performance reflects ongoing financial challenges but notable progress in key clinical trials, positioning the company for potential growth.
While facing financial constraints, the company's diversified pipeline, strategic financial decisions, and upcoming trial milestones present opportunities for future success.
Navigating the balance between financial stability, trial outcomes, and investor confidence will be critical for Panbela Therapeutics Inc's trajectory in the oncology market.

Panbela Therapeutics secures $12M funding, advances pancreatic cancer treatments

Panbela Therapeutics is on a positive trajectory with financial backing and promising clinical trial progress.
The company's focus on innovative therapies for pancreatic cancer and strategic partnerships positions it well for future growth.
While challenges exist in trial completion and program management, opportunities for advancement and collaboration are abundant.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MINNEAPOLIS, June 16, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with cancer, today announced the closing of its acquisition of Cancer Prevention Pharmaceuticals, Inc. (CPP), a private clinical stage company developing therapeutics to reduce the risk and recurrence of cancer and rare diseases, for a combination of stock and future milestone payments.

Panbela Therapeutics, Inc. Closes Acquisition of Cancer Prevention Pharmaceuticals, Inc.

Panbela Therapeutics Inc. (NASDAQ:PBLA ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants James Carbonara – Managing Partner-Hayden IR, Inc. Jennifer Simpson – Chief Executive Officer Sue Horvath – Chief Financial Officer Conference Call Participants Robin Garner – Craig-Hallum Tony Butler – Roth Capital Operator Good afternoon, ladies and gentlemen. Thank you for standing by.

Panbela Therapeutics' (PBLA) CEO Jennifer Simpson on Q1 2022 Results - Earnings Call Transcript

MINNEAPOLIS, May 12, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with cancer, today provides a business update and reports financial results for the quarter ended March 31, 2022. Management is hosting an earnings call today at 4:30 p.m. ET.

Panbela Provides Business Update and Reports Q1 2022 Financial Results

CEDARHURST, N.Y.--(BUSINESS WIRE)--Kuznicki Law PLLC is investigating the proposed sale of Cancer Prevention Pharmaceuticals, Inc. to Panbela Therapeutics, Inc. (“the Company”) (NasdaqCM: PBLA). Under the terms of the proposed transaction, holders of Panbela common stock are expected to own only approximately 59% of the post-merger holding company. If you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, contact us toll free at 833-

PANBELA THERAPEUTICS INVESTOR ALERT - Kuznicki Law PLLC Investigates Panbela Therapeutics, Inc. - PBLA

MINNEAPOLIS, April 27, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, will host an R&D call on Tuesday, May 03, 2022 at 9:00 AM Eastern Time. Panbela's management team will be joined by leading experts for a deep dive on the company's investigational drug, SBP-101, as a polyamine metabolism modulator in ovarian cancer.

Panbela to Host Virtual R&D Day

MINNEAPOLIS, April 26, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced that it will host a conference call on May 12, 2022 at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2022.

Panbela Schedules Conference Call on May 12, 2022, to Report 2022 First Quarter Financial Results

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Cancer Prevention Pharmaceuticals, Inc. to Panbela Therapeutics, Inc. (“the Company”) (NasdaqCM: PBLA). Under the terms of the proposed transaction, holders of Panbela common stock are expected to own only approximately 59% of the post-merger holding company. KSF is seeking to determine whether the merger and

PANBELA THERAPEUTICS INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Panbela Therapeutics, Inc. - PBLA

Panbela Therapeutics Inc. (PBLA) CEO Jennifer Simpson on Q4 2021 Results - Earnings Call Transcript

MINNEAPOLIS, March 24, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with cancer, today provides a business update and reports financial results for the quarter and full year ended December 31, 2021. Management is hosting an earnings call today at 4:30 p.m. ET.

Panbela Provides Business Update and Reports Q4 and FY 2021 Financial Results

MINNEAPOLIS, March 23, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, announced today that management will participate in a panel discussion titled, “Pancreatic Cancer- Turning the Tide for One of the Most Challenging Indications in Oncology,” at the Maxim Virtual Growth Conference on March 28, 2022, at 12:00 pm ET.

Panbela to Participate in a Panel Discussion: “Pancreatic Cancer- Turning the Tide for One of the Most Challenging Indications in Oncology,” at the Maxim Virtual Growth Conference on March 28, 2022, at 12:00 pm ET

MINNEAPOLIS, March 10, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, announced today that management will participate in a fireside chat at the 34th Annual Roth Conference on March 14, 2022, at 11:30AM PT. The webcast will be available at: https://wsw.com/webcast/roth43/pbla/1805948

Panbela to Participate in the 34th Annual Roth Conference

MINNEAPOLIS, March 08, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced that it will host a conference call on March 24, 2022 at 4:30 PM Eastern Time to discuss results for its fourth quarter ended December 31, 2021.

Panbela Schedules Conference Call on March 24, 2022, to Report 2021 Fourth Quarter Financial Results

Panbela Therapeutics Inc (NASDAQ: PBLA) has agreed to acquire a privately-held Cancer Prevention Pharmaceuticals Inc (CPP) for a combination of stock and future milestone payments. The combined entity will have an expanded pipeline addressing an estimated $5 billion market.

Panbela Therapeutics Acquires Cancer Prevention Pharmaceuticals For Stock & Milestone Payment

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the merger of Panbela Therapeutics, Inc. (NASDAQ: PBLA) and Cancer Prevention Pharmaceuticals, Inc. is fair to Panbela shareholders. Halper Sadeh encourages Panbela shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Panbela a

PBLA Stock Investigation: Halper Sadeh LLP Is Investigating Whether the Merger of Panbela Therapeutics, Inc. Is Fair to Shareholders

MINNEAPOLIS, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with cancer, today announced it has entered into a definitive agreement to acquire Cancer Prevention Pharmaceuticals, Inc. (“CPP”), a private clinical stage company developing therapeutics to reduce the risk and recurrence of cancer and rare diseases, for a combination of stock and future milestone payments.

Panbela Therapeutics, Inc. to Acquire Cancer Prevention Pharmaceuticals, Inc.

MINNEAPOLIS, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced the initiation of the company's global Phase 2 clinical trial of SBP-101 in combination with Gemcitabine and Nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma, which is referred to as the ASPIRE trial.

Panbela Initiates a Randomized, Double-Blind, Placebo-Controlled Study (ASPIRE) of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma

MINNEAPOLIS, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced the presentation of interim clinical data from its Phase 1b combination therapy study of SBP-101, a proprietary polyamine analogue, with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma (PDA), at the American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Meeting that took place January 20-22, 2022.

Panbela Presents Clinical Data on Phase 1b Clinical Trial of SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic PDA at 2022 ASCO GI Meeting

Data from phase 1b study using SBP-101 for patients with pancreatic cancer will be shown at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium on January 20- 22, 2022. Pancreatic cancer patients in cohort 2 given SBP-101 + chemotherapies achieved ORR of 71%; Cohort 4 patients achieved ORR of 48% but median overall survival has not yet been reached.

Panbela: Biotech With Updated Patent Protection And Unmet Market Target Indication

Company to host a virtual R&D day to discuss the new ovarian cancer program in the new year Company to host a virtual R&D day to discuss the new ovarian cancer program in the new year

Panbela Announces Positive Preclinical Data Strongly Supporting the Activity of SBP-101 in Ovarian Cancer Cell Lines; Development Program for SBP-101's Expansion into Ovarian Cancer Expected in 1H 2022

MINNEAPOLIS, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for SBP-101, a proprietary polyamine analogue, has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which will be held January 20-22, 2022.

Panbela Announces Acceptance of Abstract for Poster Presentation at American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Panbela Therapeutics Inc. (PBLA) CEO Jennifer Simpson on Q3 2021 Results - Earnings Call Transcript

MINNEAPOLIS, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today provided a business update and reported financial results for the quarter ended September 30, 2021. Management is hosting an earnings call today at 4:30 p.m. ET.

Panbela Provides Business Update and Reports Q3 2021 Financial Results

MINNEAPOLIS , Oct. 25, 2021 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc.  (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced that it will host a conference call on November 10, 2021, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2021.

Panbela Schedules Conference Call on November 10, 2021, to Report 2021 Third Quarter Financial Results

MINNEAPOLIS, Sept. 07, 2021 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that it will present at upcoming investor conferences:

Panbela to Present at Upcoming Investor Conferences

Panbela Therapeutics, Inc. (PBLA) CEO Jennifer Simpson on Q2 2021 Results - Earnings Call Transcript

News for Panbela Therapeutics Inc Stock (PBLA)